Triumeq

DRUG8 trials

Conditions

Amyotrophic Lateral SclerosisHIVHIV InfectionsHIV-DDIHIV/AIDSInfection, Human Immunodeficiency Virus

Phase 1

Interaction With HIV Antiretroviral Agents

CompletedNCT02556268

BayerHIV-DDI

Start: 2016-02-23End: 2016-12-07Updated: 2017-12-06

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

CompletedNCT02569346

Radboud University Medical CenterHIV

Start: 2016-03-31End: 2016-05-31Updated: 2020-12-07

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

CompletedNCT04827134

ViiV HealthcareHIV Infections

Start: 2021-05-07End: 2021-07-23Updated: 2023-06-05

Phase 2

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

CompletedNCT02868580

Neuroscience Trials AustraliaAmyotrophic Lateral Sclerosis

Start: 2016-10-31End: 2018-12-31Updated: 2019-08-22

Phase 3

205858

Active, not recruitingPACTR202112842892883

ViiV Healthcare UK LimitedHIV/AIDS

Start: 2022-03-10Target: 300Updated: 2026-01-27

Phase 4

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

CompletedNCT02509195

St Stephens Aids TrustHIV

Start: 2015-08-04End: 2017-07-24Target: 40Updated: 2018-02-28

Dolutegravir in Reservoirs

TerminatedNCT02924389

Emory UniversityHIV

Start: 2016-09-30End: 2019-09-11Updated: 2022-12-29

Unknown Phase

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

NCT03275701

Mills Clinical ResearchInfection, Human Immunodeficiency Virus

Start: 2016-07-31End: 2019-11-30Target: 50Updated: 2017-09-07

Proceedings of 6th International Electronic Conference on Medicinal Chemistry2020-11-05

Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2019-07-0897 citations

Pharmacokinetic (PK) interaction of fixed-dose combination (FDC) antiretrovirals (ARV) with riociguat (rio)

2018-09-151 citations

Crushing of dolutegravir fixed-dose combination tablets increases dolutegravir exposure.

2018-09-0118 citations

HIV RNA persists in rectal tissue despite rapid plasma virologic suppression with dolutegravir-based therapy.

2018-09-014 citations